Vectura Expands Dry Powder Inhaler Development & Manufacturing Capabilities
Vectura Group plc, an industry leading inhalation CDMO, recently announced an expansion of its dry powder inhaler (DPI) development and manufacturing capabilities at its facility in Chippenham, UK.
Investment has been made at the site to install a new capsule filler, a capsule blister packer, and a Mikron semi-automated device assembly machine. These enhancements will support work with capsule inhaler devices, Vectura’s open inhale close (OIC) device and the lever-operated multi-dose inhaler (LOMI) device used in Hikma’s generic Advair product, which was recently approved by the US FDA.
Work on the project has commenced and the new capabilities are scheduled to be available from Q2 2021. This expansion will significantly increase the capabilities Vectura has in DPI dosage form development, both unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.
The new semi-automated device assembly line will help meet customer demand for Vectura’s blister-based, multi-dose DPI devices, offering increased capacity to manufacture up to 1 million devices per year.
With expertise in formulation including engineered particle development, DPI device design and development, advanced inhalation analytics and GMP product and device manufacturing, customers can partner with Vectura to advance dry powder programs from early development through all clinical phases of development to small-scale commercialization.
Mark Bridgewater, Chief Commercial Officer, commented “Vectura has extensive specialist knowledge and experience in the development of dry powder inhalers, and this investment allows us to fully integrate these disciplines under one roof for pre-clinical, clinical and commercial programs. The investment in new equipment will complement existing blister-based platform capabilities to offer customers greater flexibility, alongside our other inhalation delivery platforms, to provide patients with new inhaled therapies.”
Vectura’s Chippenham facility is home to advanced science laboratories, manufacturing suites and offices where the company’s differentiated technology and skills are used to develop customers’ inhaled products, from high quality generics to novel therapies.
Vectura is a leading specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation, and development capabilities to deliver a broad range of complex inhaled therapies. Vectura has twelve key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork. For more information, please visit www.vectura.com.
Total Page Views: 1222
